Abstract:E&scedile Ba&scedilbulut, 1 Melek Bilgin, 1 Hacer I&scediller, 1 Ahmet &Scedilen, 2 Süleyman S&inodotrr&inodot K&inodotl&inodotç, 3 Mahcube Çubukçu 4 1 Department of Medical Microbiology, Samsun Training and Research Hospital, Samsun, Turkey; 2 Department of Anesthesia and Reanimation, Trabzon Faculty of Medicine, Trabzon, Turkey; 3 Department of Infectious Disease and Clinical Microbiology, Samsun Training and Research Hospital, Samsun, Turkey; 4 Department of Family Medicine, Samsun University Faculty of Medicine, Samsun, Turkey Correspondence: Mahcube Çubukçu, Tel +905052332232, Fax +903623111522, Email Background: The objective of this study is to compare the measles immunoglobulin G (IgG) and rubella IgG levels in patient groups with mild and severe COVID-19 disease and reveal the possible relationship. Methods: This study was conducted among COVID-19-confirmed patients over 18, under 65 years of age. This study involved 75 participants- divided into two groups. The first group usually comprised asymptomatic patients who did not require hospitalization (n=43), and the second group consisted of patients who had diffuse pneumonia on thoracic CT and required hospitalization (n=32). Results: Anti-measles and anti-rubella IgG titers were detected to be higher in the group with severe disease compared to the group with mild disease (p=0.001 and p=0.001, respectively). The analyses were repeated by taking n=27 in Group 1 and n=27 in Group 2, which were similar in terms of age, gender and number. In the analysis performed without any age difference between the groups, no significant difference was found between the two groups in terms of Anti Measles IgG antibody titers (p=0.068). However, Anti Rubella antibody titers were found to be higher in the group with severe COVID-19 disease than in those with mild disease (p=0.03). Regardless of the severity of the disease, there was a positive correlation between Anti Rubella and Anti Measles IgG antibody titers and age (p=< 0.001 Spearman's rho 0.517; p=0.008 Spearman's rho 0.304, respectively). Conclusion: We believe that the pre-existing Anti-Rubella IgG antibodies in the patient may increase in parallel with the patient's viral load by recognizing the common macrodomain of SARS-CoV-2 and Rubella viruses. The common macrodomain of SARS-CoV-2 and Rubella viruses is also present in the attenuated rubella virus used in the MMR vaccine4. In this case, we predict that previously administered MMR vaccine may be protective for COVID-19 patients. disease compared to those with mild disease. Keywords: COVID-19, measles, rubella, antibody, SARS-CoV-2, immunoglobulin G The clinical course of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection may be asymptomatic, or it may result in respiratory failure, pneumonia, and death. 1 The world continues to witness the rapid transformation of the SARS-CoV-2 virus with the Omicron variants (BA.1, BA.2, BA.3, BA.4, and BA.5) of the SARS-CoV-2 virus. The continuous change of Omicron variants brings about considerable challenges in establishing herd immunity for SARS-CoV-2. 2 However, vaccines help significantly reduce disease severity. 3 The fact that COVID-19 vaccines and effective antiviral drugs are still inaccessible in middle- and low-income countries and inequality in access to vaccines increase the risk of COVID-19 infection in low-income countries, mostly in Africa, and the likelihood of the emergence of new variants of the SARS-CoV-2 virus. 2,3 Studies have reported that COVID-19 infection is severe, especially in the elderly and adult population with a single comorbidity, while the disease progresses with mild symptoms in young people and the pediatric age group. 4–6 Likewise, it has been stated in the literature that children are less likely to be infected in other epidemics with viruses from the same family as the SARS-CoV-2 virus, such as severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS). 7 A reason for this difference may be associated with the more recent immunization of children with multiple vaccines such as Bacillus Calmette–Guérin (BCG), Diphtheria-Pertussis and Tetanus (DPT), hepatitis B, polio, and Measles-Mumps-Rubella (MMR). 8 Furthermore, some vaccines, such as BCG, may provide cross-protection against other pathogens not related to Mycobacterium tuberculosis. 9 The BCG vaccine has been shown to provide non-specific protection against pathogens such as Candida albicans, Staphylococcus aureus, and various respiratory viruses. 10–13 The said type of immu -Abstract Truncated-

Measles and Rubella Serosusceptibity Among Population Vaccinated with Different Schedule of Vaccination: The Potential Impact on Measles Elimination in Iran.

Measles and rubella serosusceptibity among population vaccinated with different schedules: the potential impact on measles-rubella elimination in Iran

Monitoring the Efficacy of Infant Hepatitis B Vaccination and Revaccination in 0- to 8-Year-old Children: Protective Anti-Hbs Levels and Cellular Immune Responses.

Rubella Immunity in Women of Childbearing Age, Eight Years After the Immunization Program in Iran

Humoral and cellular immunity to measles and rubella virus antigens in healthy subjects

Evaluating the effect of measles and rubella mass vaccination campaigns on seroprevalence in India: a before-and-after cross-sectional household serosurvey in four districts, 2018-2020

Immunogenicity and safety of measles, mumps and rubella combined attenuated live vaccine in revaccination of children and in vaccination of childbearing-age women

A Serological Survey of Measles and Rubella Antibodies among Different Age Groups in Eastern China

Seroepidemiology of measles and rubella among Hong Kong young adults and the humoral responses of an MMR booster among participants with low antibody levels

Evaluating effective measles vaccine coverage in the Malaysian population accounting for between-dose correlation and vaccine efficacy

Analysis of Measles and Rubella Immunoglobulin G Titers in COVID-19 Patients

Using Regular High-Quality Serosurveys to Identify and Close National Immunity Gaps—Measles and Rubella Elimination in Japan

Evaluation of the focus reduction neutralization and ELISA tests compared to the plaque reduction neutralization test for the detection of antibodies against measles virus

Age-specific prevalence of IgG against measles/rubella and the impact of routine and supplementary immunization activities – a multistage random cluster sampling study with mathematical modelling

Evaluation of age-related distribution of measles cases with primary and secondary immune response in Russian Federation, 2010-2016

Laboratory monitoring of postvaccination measles immunity

Elimination of endemic measles and rubella transmission in Oman

Measles and rubella seroprevalence in adults using residual blood samples from health facilities and household serosurveys in Palghar District, Maharashtra, India, 2018 – 2019

Measles, Mumps, and Rubella Revaccination in Children after Completion of Chemotherapy and Hematopoietic Stem Cell Transplantation: a Single-Center Prospective Efficacy and Safety Analysis

Formation of humoral and cellular immunity to measles vaccine in adults

Rubella immunity among pregnant women and the burden of congenital rubella syndrome (CRS) in India, 2022